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stage I and 11 cancer
Tumour excision, axillary dissection, peri-operative interstitial irradiation,
with or without peri-operative chemotherapy, followed by breast
irradiation - the Tygerberg Hospital experience
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Summary
Since 1984 breast-conserving treatment has been the treat-
ment of choice for patients at Tygerberg Hospital with early
breast cancer. Peri-operative interstitial brachytherapy in
breast cancer is described in detail. In the 221 patients
treated (225 breasts), 197 breasts received iridium implants
and 26 patients received peri-operative chemotherapy
(POPFAC). There were 6 recurrences in treated breasts, 3
within the booster area and 3 outside. There were 5 salvage
mastectomies, and 1 patient was treated by excision and
radiotherapy. Metastases developed in 27 patients. Two
patients underwent mastectomy for severe radiation changes
and 7 developed postoperative wound infection after POPFAC.
Five patients, who had re-excisions and prolonged seroma
formation, developed delayed wound infection after POPFAC.
Five patients, who had re-excisions and prolonged seroma
formation, developed delayed wound infection. The impor-
tance of mammography, patient selection, tumour-free margins
and radiation dosage are discussed.
SAIr Med J 1989; 75: 519-523.
The results of breast-conserving treatment (BCT) are equivalent
to mastectomy in terms of local recurrence, relapse-free survival
and overall survival. I- 4
However, many aspects - optimal method of boosting,
optimal radiotherapy dose required, long-term effects of radio-
therapy on normal as well as on premalignant breast tissue and
the need for routine axillary clearance - are unresolved. Since
1984 the Tygerberg Hospital Breast Clinic has participated in
the randomised trial of the European Organisation for Research
and Treatment of Cancer (EORTC) on BCT v. mastectomy.
Results of this multicentre trial have been reported by the
study co-ordinators.5
Our methods and the experience gained in BCT are described
in detail, with emphasis on peri-operative interstitial radio-
therapy about which there have been few reports.
Patients and methods
All patients presenting primarily at this clinic were evaluated
and assessed for treatment by both the surgeon (J.v.Z.) and
radiotherapist (A.G.S.M.) Similarly, all patients referred after
surgery were re-staged before radiotherapy began.
Breast Clinic, Departments of Surgery and Radiotherapy,
University of Stellenbosch and Tygerberg Hospital, Parow-
valiei, CP
J. A. VAN ZYL, RSC., M.MED. (CHIR.)
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Accep,ed 8 Aug 1988.
The patient population consisted of 221 patients, treated
between February 1984 and December 1987. Of the 225
breasts, 135 were treated primarily at Tygerberg Hospital and
86 were referred postoperatively by private surgeons for radio-
therapy.
The age distribution with each diagnosis of cancer in 10-
year age groups was: 20-29 years - 7 patients, 30-39 - 50,
40-49 - 54, 50-59 - 42,60-69 - 49, and 70-74 - 23. At the
time of diagnosis of each tumour 115 patients were premeno-
pausal and 109 postmenopausal, the menopausal status of I
patient was not recorded. The tumours were staged by UICe
TNM criteria: 65 had stage I disease and 160 stage H. One
hundred and fourteen tumours occurred in the right breast
and 107 in the left, a second tumour in the opposite breast
occurred in 4 patients. The quadrants involved were: upper-
outer 108, lower-outer 31, upper-inner 58, lower-inner 22 and
central 6. Three patients had bilateral metachronous and I had
bilateral synchronous breast carcinoma.
Pre-operative evaluation
Pre-operative evaluation included chest radiography, limited
skeletal survey, blood chemistry investigation, full blood count,
bone scan and mammography. The diagnosis was confirmed
by fIne-needle aspiration cytology.6 If this modality was un-
successful, or if a papillary neoplasm was reported, an excision
biopsy was performed followed by defInitive treatment a week
later.
Tumour excision
The skin incision was made directly over the tumour. A small
ellipse of skin directly overlying the tumour was excised,
minimising flap dissection. In the upper half of the breast, the
incision conformed with the lines of Langer and in the lower
half a vertical incision, which minimised distortion of the
breast, was preferred. The tumour and 1 - 2 cm of surrounding
normal breast tissue was excised. The incision extended down
to the pectoralis fascia. It was important to palpate the wound
area for any remaining suspect tissue. The· specimen was
sectioned to determine macroscopically whether all tumour
was excised and to measure the tumour diameter. If the
borders seemed to be marginal, these areas were re-excised.
No anempt was made to approximate the breast tissue by
suturing. The wound was closed by a single layer of sub-
cutaneous polyglactin sutures. The wound was drained by a
small rubber drain for 4-5 days. To ensure tumour-free
margins, patients diagnosed at an outside hospital all underwent
re-excision of the biopsy site.
Axillary lymph node dissection
The axillary lymph node dissection was preferably performed
through a separate incision, except for tumours situated near
520 SAMT VOL 75 3 JUN 1989
the axilla, which were excised in continuity with the axillary
lymph node dissection. The incision was made anteroposteriorly,
crossing the axillary fossa in a downward direction. The
pectoralis minor muscle was cut at its origin to facilitate
complete removal of the lymph nodes up to the apex of the
axilla. During the operation the boundaries of the lower,
higher and apical lymph node regions were marked with
coloured beads to ensure accurate sectioning of the specimen.
The thoracodorsal neurovascular bundle and nerve to the
latissimus dorsi were preserved. The skin incision was closed
with a single layer of continuous subcutaneous polyglactin
sutures. The wound was drained by a suction drain.
Radiotherapy technique
Iridium-192 implant as a booster
We used an afterloading technique to deliver the booster
dose of radiation. The target area was determined during
surgery. If the excision was macroscopically complete, the
target area comprised the tumour diameter plus 1 cm on either
side. If there was any doubt about the excision margin, the
target area was increased to the tumour diameter plus 2 cm on
either side. The distribution and number of wires was deter-
mined by the activity of the iridium wire. Templates were
used to position and maintain the needles. In single-plane
implants the distance between sources was 10 mm. In double-
plane implants it varied between 15 mm and 20 mm. We
preferred double-plane implants.
With the wound open, the first of two rows of hollow
stainless-steel needles was inserted through the tumour bed.
The wound was then sutured and the second row of needles
inserted. The needles had to be positioned a minimum distance
of 10 mm from the skin. The templates and needles were held
in position by lead crimps. To remove any tissue debris from
the lumen of the hollow needle, a thin solid needle was pushed
through it. The sharp end of the needle was cut off, sealing the
end. The tumour area was marked on the skin. Thin plastic
tubing, 1 mm in diameter, was inserted into each needle,
creating a dead space from the needle end to the target area.
The iridium wires were loaded 2 days after surgery. A dosage
of 10 Gy/ d, with a total dose of 25 Gy (calculated on the 85%
isodose curve), was given.
Patients referred after. tumour excision and axillary lymph
node dissection received the booster dose by implant 2 weeks
after completion of external beam therapy or 1 week before
external irradiation was started.
The rules of the Paris system7 were followed when calculating
the dose.
External beam booster
Where an implant was not feasible, the booster dose was
given by external beam therapy. The treatment was planned
with two wedge fields to the tumour bed. A tumour dose of 20
Gy in 10 fractions was given after completion of the irradiation
to the whole breast.
External beam therapy technique
The whole breast was treated by external beam therapy 3-4
weeks after surgery. Two tangential fields were used. The
limits of the fields were 2 cm above and below the breast.
Treatment was planned using wedge or compensating filters
and lung corrections were made routinely.
Dosage
A tumour dose of 50 Gy was delivered by cobalt-60 radiation
in 25 fractions of 2 Gy tumour dose over 5 weeks. The dosage
variation within the treated area was less than 10%.
Technique of treatment planning
Planning was performed with the use of computed tomo-
graphy (CT). With the patient supine, arms elevated and
hands under the head, the upper and lower limits of the breast
fields were marked on the skin. A single CT view through the
central plane was obtained to delineate the breast and under-
lying lung for planning purposes.
Internal mammary lymph node irradiation
Seventy-three patients with centrally and medially located
tumours received internal mammary irradiation. A given dose·
(GD) of 50 Gy in 25 fractions of 2 Gy was administered.
Supraclavicular irradiation
Twenty-three patients with apical lymph node or extranodal
involvement received supraclavicular irradiation. A GD of 50
Gy in 25 fractions of 2 Gy was adminstered.
Adjuvant chemotherapy
Fifteen premenopausal lymph node-positive patients received
adjuvant cyclophosphamide, methotrexate and 5-fluoro-uracil
(CMF) chemotherapy for 6 courses. These patients were part
of the EORTC trial.5 Twenty-six patients received a single
dose of cyclophosphamide, adriamycin and 5-fluoro-uracil
(CAF) 24 hours postoperatively. These patients form part of
an ongoing EORTC trial.8
Pathological examinations
To ensure consistency in pathological reports all material
was evaluated by one pathologist. The following features were
specifically noted: tumour differentiation; presence and extent
of ductal carcinoma in situ; presence of tumour on the excision
margin; level of nodal involvement; extranodal involvement;
and presence of tumour in soft tissue.
Oestrogen and progesterone receptor content were deter-
mined according to the method of McGuire et al.9
Results
The 221 patients were followed up for 5-52 months and 225
breasts were treated. Two patients had undergone mastectomy
previously for contralateral breast cancer.
In 139 axillas the lymph nodes were not involved in the
disease process. Lymph node involvement was present in 83
axillas: 55 had 1-3 nodes, 22 had 4-9 nodes, and 6 more than 9
nodes involved. In 9 axillas the apical lymph nodes were
involved.
In 30 patients the axillary lymph node clearance and tumour
excision had to be performed $ough a single incision. In 3
patients (over 70 years of age with medially located tumours
and clinically normal axillas) no axillary lymph node clearance
was performed.
One hundred and ninety-seven breasts received iridium
implants as booster therapy; 126 of these implants were
positioned intra-operatively.
Recurrence
Three patients developed local recurrence within the booster
area. On review, 2 had had inadequate excision of the primary
tumour, 1 patient having had 2 tumours. Both patients were
treated within the first 3 months of the study period. Both
underwent salvage niastectomy and subsequently developed
metastatic disease. One has died. The third patient was 28-
years-old and her tumour had an extensive intraductal com-
ponent. Salvage mastectomy was performed for the recurrent
tumour, which on pathological examination consisted almost
entirely of ductal carcinoma in siru. This patient is disease-free
at present.
Three patients developed a second tumour outside the
booster area. On pathological examination one tumour had no
intraductal component and was classified as a true recurrence,
the other 2 patients, who had associated intraductal carcinoma,
were regarded as having second primary tumours. One of
these patients was tre.ated by tumour excision and iridium
implant to 30 Gy. Twenty-four months later, she remained
free of disease. The remaining 2 patients were treated by
mastectomy. One developed metastatic disease and is alive, the
other remains free of disease. On review of their original
mammograms, 1 patient had microcalcifications, which had
been overlooked, in the area where the subsequent tumour
developed.
Seven subsequent mastectomies have been performed in
this series, 5 for recurrent disease as described above. Two
patients with very large breasts had a mastectomy for severe
symptomatic radiation changes. One of our patients developed
non-related malignant disease of the cervix. She remains free
of mammary disease.
Metastases
In total 27 patients developed metastatic disease. Two of
these presented simultaneously with metastases and diffuse
recurrence within the breast. Both were referred patients, 1 of
whom, on review, had had residual macroscopic tumour during
surgery for the primary tumour. One of these patients has
died, the other has stable disease on chemotherapy. The
remaining patients with metastatic disease are free from local
recurrence.
Deaths
Nine patients died, 6 of metastatic disease and 3 of unrelated
causes. Only 1, already mentioned, had evidence of local
recurrence at death.
Wound infection occurring before
completion of radiotherapy
Two patients developed infection of the tumour excIsion
wound, 1 of whom had received peri-operative CAF. Four
patients developed infection of the axillary wound, 3 had
received peri-operative CAF. One patient, who received peri-
operative CAF, had infection at both sites. This patient was
confused postoperatively and pulled out all her drainage tubes.
Wound infection at the tumour excision scar
This occurred in 5 patients 4 - 8 months after completion of
therapy. All developed the infection in a persistent seroma.
Four of these had undergone biopsy elsewhere and had re-




We considered all patients up to 75 years of age for BCT,
since patients over 75 years are treated by tumour excision and
tamoxifen.8 In our experience the elderly patient is as keen to
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retain her breast as the young woman. Four of 6 patients with
local recurrence were under 40 years of age at the time of.
diagnosis, which is in accordance with the findings of Recht el
al. IQ These patients, particularly if a marked degree of carci-
noma in silu is present, require very careful follow-up. This,
however, does not imply that a young woman should not be
considered for BCT. IO- 13
Mammography
In all patients considered for BeT, high-quality film
mammography is mandatory. With this examination,14 multiple
tumours, diffuse microcalcifications indicative of possible wide-
spread carcinoma in siru or infiltrating carcinoma and poorly
circumscribed tumours, which may indicate wide infiltration,
can be diagnosed. Patients with these features should not be
considered for BCT. The local recurrence in 2 of our patients
could be attributed directly to poor quality mammography,
not observing additional microcalcifications in I case and
multiple tumours in the other.
Tumour size
We regard a tumour size of 4 cm as the. upper limit of
suitability for BCT. Larger tumours necessitate more extensive
surgery and a larger booster area, resulting in poor cosmesis
and increased risk of local recurrence. Patients with inadequate
excision have been reported to have only 66% local control
opposed to 89% with complete excision. IS
Breast size
Breast size is a relative contraindication to BCT. In our
experience only 1 patient had a breast too small for BCT since
tumour excision would have removed all her breast tissue. We
find very large breasts a more serious problem. There are
technical problems associated with radiotherapy, i.e. patient
positioning is very difficult and dosage distribution is not
homogeneous, leading to unacceptable fibrosis, as experienced
in 2 patients. BCT with simultaneous bilateral breast reduction
could possibly be considered for these patients, since a
mastectomy results in unacceptable postural problems, a fact
often ignored by the surgeon.
Surgery
Incision
It is important to make the incision directly over the
tumour. 16 Subcutaneous dissection from a circumareolar in-
cision towards a peripherally located tumour is likely to result
in an incomplete excision and an increased risk of local
recurrence, as experienced in I of the referred patients. Large
excisions in the upper quadrant often lead to nipple displace-
ment and, if this is anticipated, the areola should be dissected
free from the underlying breast tissue even if this necessitates
cutting the milk ducts. 3 Incisions made along the lines of
Langer for lower quadrant tumours, tend to fix the breast
against the chest wall. A radial incision avoids this complication.
If the lower part of the excision traverses the inframammary
fold, a diamond-shaped incision gives extra length to the
wound and maintains breast mobility.
Extent
A tumour excision with 1-2 cm surrounding breast tissue,
which is our policy, is sufficient. Quadrantectomy and seg-
mental resections are no longer justified because cosmesis is
poor and local control and survival are not superior to lesser
surgery and adequate radiotherapy.3-S,IS
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Tumour-free margins
The importance of a tumour-free marRin and the necessity
to boost the tumour bed is controversial. ,17,18 Our policy is to
achieve a macroscopically tumour-free margin and to boost the
tumour bed. It is therefore important that the surgeon should
palpate the inside of the wound for residual cancerous areas
thoroughly. On occasion we have detected an unsuspected
second tumour. We believe the surgeon should transect the
specimen during surgery to judge whether the margins are free
of tumour, to measure the diameter and to verify the centre of
the rumour, which is usually eccentrically placed in the
specimen, If the tumour-free area is marginal, a further excision
can be done immediately and accurately. A further advantage
is that we are then able to adjust the booster area to encompass
the area at risk. We regard this as a major advantage of intra-
operative brachytherapy. A disadvantage of transecting the
tumour is the fact that the pathological assessment of inked
margins, which is standard practice, is more difficult,17 We
subject all patients referred after a diagnostic biopsy to re-
excision biopsy to achieve the goal set out above. 19
Axillary lymph node dissection
The extent and need for axillary lymph node dissection
remain controversial. 20,21 Our policy is to perform a complete
axillary lymph node clearance, which ensures excellent local
control and selects patients who qualify for supraclavicular
irradiation. Axillary lymph node irradiation, with its associated
morbidity, is thus not indicated.22 In our experience a recur-
r-ence at the apex of the axilla after partial axillary lymph node
dissection is extremely difficult to control.
Almost 60% of our patients were lymph node-negative on
pathological examination and could possibly have been managed
without axillary lymph node dissection.20 However, clinical
examination of the axilla is inaccurate in 30% of patients and
there are no diagnostic imaging methods available to demon-
strate axillary lymph node involvement.23 Axillary lymph node
sampling is utilised by some authors as an indicator for full
axillary lymph node clearance or irradiation of the axilla. In
practice, all patients should undergo axillary lymph node
clearance until the question of delayed axillary lymph node
clearance is clarified in a prospective study.
Nine of our patients had clinically undiagnosed apical lymph
node involvement, which explains the rationale behind the
treatment at institutions such as the Netherlands Cancer Insti-
tute, which practises apical lymph node biopsy before defini-
tive treatment. The morbidity associated with axillary lymph
node clearance includes prolonged hospitalisation owing to
axillary drainage, risk of oedema of the arm, greater oedema of
the breast and risk of impaired shoulder function. 2o,22
Attempts to reduce the period of seroma formation, i.e. late
mobilisation of the shoulder, early removal of the drains with
repeated aspiration and pressure bandages, and the use of
fibrin glue have all been unsuccessfuJ.24
Irradiation
Iridium implant
The importance of irradiation of the breast as well as
adequate dosage is emphasised by the high rates of recurrence
reported in the US National Surgical Adjuvant Breast Protocol4
and Guy's Hospital25 studies,
The data of Harris and Hellman1s emphasise the importance
of both tumour excision and booster to the tumour bed. Their
6-year rate of local rumour control was 89% for patients who
had undergone excisional biopsy compared with only 66% for
patients who had not. The 6-year risk of a recurrence of the
primary tumour was 12% for patients who had not received a
boost compared with 6% for those who had.
As some others, we prefer giving the booster dosage by an
1921 implant at the time of surgery,19 The advantages of this
technique are that needles are placed accurately under direct
vision, the surgeon can identify suspect areas, dosage is accu-
rately delivered, a single anaesthetic is required, hospitalisation
is not prolonged, and overall treatment time is shorter in
comparison with an external booster or delayed implant.
Initially we used polythene tubing as described by Paine26
in our implants. Source geometry and therefore dosage distri-
bution were very uneven. We therefore changed to the rigid
needle and template technique, Templates were made to our
specifications by our physics laboratory technicians, This tech-
nique ensures that the sources remain parallel and straight.
The use of stainless-steel needles reduces the dosage by less
than 2%, as calculated by our physicists, The needles and
templates are held in position by lead crimps, which are
always available and are simpler to use than many complicated
devices. The implant causes minimal discomfort and is removed
painlessly, An afterloading apparatus is commercially available
but only 1 patient can be treated over a period of 2 days. This
is impractical and not cost-effective in our situation.
We use the Paris system7 because of its flexibility and
adaptability to individual clinical situations.n Therefore we
are able to use single-plane implants in certain situations with
insufficient breast tissue, such as the upper inner quadrant.
Double-plane implants, which treat a larger volume, are pos-
sible in virtually all other situations. Care should be taken to
deliver the implant dosage at least 5 mm from the skin surface
in order to minimise skin reaction and fibrosis, which causes
poor cosmesis,
The optimal dosage for the booster has not been established.
Trials to establish the efficacy of higher and lower dosages are
in progress.
External beam therapy
Dosage is limited to 2 Gy fractions. IS Increasing the daily
dosage causes increased fibrosis with poor cosmesis. The skin
dose is limited by the use of wedge or compensating filters,
bolus is not used.
Where sternal or supraclavicular fields are treated, great
care must be exercised to ensure that fields do not overlap.
This causes marked fibrosis and poor cosmesis.
Local recurrence
We classify recurrent disease as: (I) a recurrence occurring
within the booster area; (il) a tumour occurring outside the
booster area within the irradiated area - this may represent a
true recurrence or another primary tumour; and (iil) a tumour
occurring outside the irradiated area, which we consider a
metastasis.
The discovery of a lump is equally traumatic for doctors and
patients and both tend to overreact, accepting that it is malig-
nant. Of 17 patients presenting with a recurrent lump, only 7
ultimately proved to have malignant disease in a review of 214
patIents treated at Guy's Hospital, London.28
The factors associated with a high incidence of local recur-
rence are: 3:4,10,13,15,17 (i) positive axillary lymph nodes;
(il) residual tumour at the resection line; (iil) extensive car-
cinoma in situ in and surrounding the tumour; (iv) increasing
size of the tumour; and (v) young age.
Scarring and fibrosis in the breast surrounding the tumour
excision, and the presence of benign breast disease makes the
recognition of recurrent carcinoma difficult. 27 The mammo-
graphic signs indicative of carcinoma are a mass lesion or new
malignant-type microcalcifications, Other signs are nonspecific
and common after tr-eatment. Annual follow-up mammo-
graphy, starting 6 months after surgery, is. strongly recom-
mended.
On pathological examination, radiation-induced changes in
normal breast tissue may bc indistinguishable from carcinoma.
Great care must be taken in the interpretation of fine-needle
aspiration of recurrent lumps in the breasr.29 Histopathological
confirmation, which could also be difficult, must be obtained
before any treatment decision is made.30 It is thus advisable
that these patients are followed up by clinicians with experience
of post-radiation changes. It must be emphasised that local
recurrence in a conservatively treated breast does not have the
same implication in terms of poor prognosis as' local recurrence
after mastectomy. 15
The treatment of local recurrence depends on the site and
extent of recurrence. We perform a mastectomy for recurrence
within the booster area. Early resectable recurrent disease
elsewhere may be treated by re-excision and an interstitial
booster. 15 Recurrence outside the treatment area is regarded as
metastatic disease and should be treated accordingly.
Metastases
In reported randomised trials patients undergoing BCT
have the same incidence of metastatic disease as those under-
going mastectomy.3.S
Wound infection
Peri-operative brachytherapy per se has not been associated
with wound infections or delayed wound healing in our ex-
perience. 19 Early wound infection invariably occurred in
patients receiving peri-operative CAF. We experienced the
same problems in mastectomy patients receiving peri-operative
CAF. In all our cases late wound infection was associated with
persistent seroma formation following re-excision biopsy. These
patients did not respond to antibiotics and wound drainage.
Primary healing could only be obtained by excision of the
cavity and surrounding indurated tissue. To prevent this com-
plication, the drain must not be removed prematurely.
Conclusions
At Tygerberg Hospital a dramatic change in the treatment of
stage I and II breast cancer has been observed during the past
5 years. BCT is now our accepted method of treatment.
We have demonstrated that by integrating sound surgical
and radiotherapeutic principles, excellent local control and
cosmesis can be achieved without compromising survival. In
our experience intra-operative brachytherapy has many
advantages without increasing postoperative morbidity. Used
with care, peri-operative chemotherapy can be adminstered
simultaneously.
Although not specifically evaluated in this study, it is
apparent that the treatment options for stage I and stage II
breast cancer are not widely known and BCT is not generally
practised.
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